ArticleRespiratory research2026
Anti-heparanase shields against endothelial dysfunction in a rat model of warm pulmonary ischemia-reperfusion.
Article in Respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
backgroundPrimary graft dysfunction (PGD) occurs within the first three days after lung transplantation (LT), primarily due to ischemia–reperfusion (I/R) injury. Heparanase is an enzyme involved in I/R mechanisms. We investigated the effects of heparanase inhibition using derivative from λ-Carrageenan referred to as “Carrageenan”, and Heparin on endothelial dysfunction, inflammation, and glycocalyx integrity in a warm I/R rat model.
methodsThree groups of male Wistar rats were studied: Control (NaCl 0.9%)(n = 14), Heparin (n = 14), and Carrageenan (n = 16). Rats underwent 1 h of left pulmonary warm ischemia. The reperfusion period was 3 h for one subgroup (H3) and 3 days for another (D3). Pulmonary artery endothelium-dependent and independent relaxation to acetylcholine and sodium nitroprusside respectively were analyzed using a wire myograph, with a Sham group (without I/R) for comparison. Pulmonary inflammation markers were assessed by RT-qPCR and immunohistochemistry, while glycocalyx degradation and systemic inflammation markers were evaluated using enzyme-linked immunosorbent assays (ELISA). Data were expressed as mean ± SD for all analyses, except vascular function (mean ± SEM). Normality was assessed using Kolmogorov–Smirnov and Shapiro–Wilk tests. Kinetic data were analyzed using one-way repeated-measures ANOVA or, when non-normal, the Friedman test. Other data were analyzed using one-way ANOVA or the Kruskal–Wallis test for non-normal distributions. Tukey or Dunn’s post hoc tests were applied, respectively, to identify significant differences between groups (p < 0.05).
resultsEndothelial dysfunction was observed in the Control and Heparin groups, with reduced pulmonary vasorelaxation to acetylcholine compared to the Sham group, without change in endothelium-independent relaxation. In contrast, Carrageenan preserved endothelium-dependent relaxation. Moreover, Carrageenan reduced macrophage and lymphocyte infiltration, as well as lung inflammation (IL-6 and TNF-α) compared to the Control group at H3. Carrageenan also showed pulmonary anti-inflammatory effects at D3. However, Carrageenan did not reduce circulating levels of markers of glycocalyx degradation or systemic inflammation.
conclusionCarrageenan protects against pulmonary endothelial dysfunction and exerts strong pulmonary anti-inflammatory effects. It may serve as a protective agent against I/R injury in LT, potentially limiting the risk of primary graft dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.